Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: Subanalysis of the prevention of vte after acute ischemic stroke with LMWH (PREVAIL) study

Stroke

Volumn 40, Issue 11, 2009, Pages 3532-3540

  Kase, Carlos S ^a   Albers, Gregory W ^b   Bladin, Christopher ^c   Fieschi, Cesare ^d   Gabbai, Alberto A ^e   O'Riordan, William ^f   Pineo, Graham F ^g  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c MONASH UNIVERSITY   (Australia)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f Paradise Valley Hospital   (United States)

^g UNIVERSITY OF CALGARY   (Canada)

Author keywords

Intracerebral hemorrhage; Ischemic stroke; Venous thromboembolism

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

AGED; BRAIN ISCHEMIA; ENOXAPARIN; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; STROKE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 70350521870     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.555003     Document Type: Article

References (27)

1. McCarthy ST, Turner JJ, Robertson D, Hawkey CJ, Macey DJ. Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet. 1977;2:800-801.
2. McCarthy ST, Turner J. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age Ageing. 1986;15:84-88.
3. Kelly J, Rudd A, Lewis R, Hunt BJ. Venous thromboembolism after acute stroke. Stroke. 2001;32:262-267.
4. Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ. Stroke Council of the American Stroke Association. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003;34:1056-1083. (Pubitemid 36402991)
5. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(suppl):483S-512S.
6. Cardiovascular Disease Educational and Research Trust; Cyprus Cardiovascular Disease Educational and Research Trust; European Venous Forum; International Surgical Thrombosis Forum; International Union of Angiology; Union Internationale de Phlébologie. Prevention and treatment of venous thromboembolism. International consensus statement (guidelines according to scientific evidence). Int Angiol. 2006;25: 101-161
7. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997; 349:1569-1581.
8. Hillbom M, Erilä T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurol Scand. 2002;106:84-92.
9. Diener HC, Ringelstein EB, von Kummer R, Landgraf H, Koppenhagen K, Harenberg J, Rektor I, Csányi A, Schneider D, Klingelhöfer J, Brom J, Weidinger G; PROTECT Trial Group. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. Stroke. 2006;37: 139-144.
10. Shorr AF, Jackson WL, Sherner JH, Moores LK. Differences between low-molecular-weight and unfractionated heparin for venous thrombo-embolism prevention following ischemic stroke: a metaanalysis. Chest. 2008;133:149-155.
11. McRae SJ, Ginsberg JS. Initial treatment of venous thromboembolism. Circulation. 2004;110(suppl 1):I3-I9.
12. Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, O'Riordan W, Pineo GF; PREVAIL Investigators. The efficacy and safety of enoxaparin versus unfractionated heparin for the PREvention of Venous thromboembolism after Acute Ischaemic Stroke (PREVAIL study): an open-label randomised comparison. Lancet. 2007;369: 1347-1355.
13. Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, Chan FL, Fong KY, Law CB, Wong A. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995;333: 1588-1593
14. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight hep-arinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA. 1998;279:1265-1272.
15. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet. 2000;355: 1205-1210.
16. Bath PM, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, Marttila R, Olsson J, O'Neill D, Orgogozo J, Ringelstein B, van der Sande J, Turpie AG. Tinzaparin in Acute Ischaemic Stroke (TAIST): a randomised aspirin-controlled trial. Lancet. 2001;358:702-710.
17. Wong KS, Chen C, Ng PW, Tsoi TH, Li HL, Fong WC, Yeung J, Wong CK, Yip KK, Gao H, Wong HB; FISS-tris Study Investigators. Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study. Lancet Neurol. 2007;6:407-413.
18. Sherman DG, Soltes S, Samuel R, Chibedi-Deroche D. Enoxaparin versus unfractionated heparin in the prevention of venous thromboembolism after acute ischemic stroke: rationale, design, and methods of an open-label, randomized, parallel-group multicenter trial. J Stroke Cereb Dis. 2005;14:95-100.
19. Hosmer DW Jr, Lemeshow S. Applied Logistic Regression, 2nd ed. New York: John Wiley & Sons, Inc; 2000.
20. Broderick J, Brott T, Kothari R, Miller R, Khoury J, Pancioli A, Gebel J, Mills D, Minneci L, Shukla R. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 1998;29:415-421.
21. Sacco RL, Boden-Albala B, Gan R, Chen X, Kargman DE, Shea S, Paik MC, Hauser WA. Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. Am J Epidemiol. 1998;147:259-268.
22. Prabhakaran S, Wright CB, Yoshita M, Delapaz R, Brown T, DeCarli C, Sacco RL. Prevalence and determinants of subclinical brain infarction: the Northern Manhattan Study. Neurology. 2008;70: 425-430.
23. Sacco RL, Boden-Albala B, Abel G, Lin IF, Elkind M, Hauser A, Paik MC, Shea S. Race-ethnic disparities in the impact of stroke risk factors: the Northern Manhattan Stroke Study. Stroke. 2001;32:1725-1731.
24. Libman R, Kwiakowski T, Lyden P, Grotta JC, Tilley BC, Fagen SC, Levine SR, Broderick JP, Lin Y, Lewandowski C, Frankel MR; NINDS rt-PA Stroke Study Group. Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long-term outcome. J Stroke Cere-brovasc Dis. 2005;14:50-54.
25. Dzialowski I, Pexman JH, Barber PA, Demchuk AM, Buchan AM, Hill MD. CASES Investigators. Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian alteplase for stroke effectiveness study registry. Stroke. 2007;38:75-79.
26. Sprigg N, Gray LJ, Bath PM, Lindenstrøm E, Boysen G, De Deyn PP, Friis P, Leys D, Marttila R, Olsson JE, O'Neill D, Ringelstein EB, van der Sande JJ, Turpie AG; TAIST Investigators. Stroke severity, early recovery and outcome are each related with clinical classification of stroke: data from the 'Tinzaparin in Acute Ischaemic Stroke Trial' (TAIST). J Neurol Sci. 2007;254:54-59 (Pubitemid 46343741)
27. The CLOTS Trials Collaboration. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomized controlled trial. Lancet. 2009;373:1958-1965.